BioCentury
ARTICLE | Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

August 12, 2019 11:23 PM UTC

Jazz gains essential tremor asset via Cavion takeout
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal that gives Jazz CX-8998. While the calcium channel T-type blocker missed the primary endpoint in a Phase II trial last year for moderate to severe essential tremor, Jazz said the first-in-class compound demonstrated proof-of-concept in the study and plans to start a Phase II trial in 2020.

Boehringer, MD Anderson in cancer collaboration
Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with the University of Texas MD Anderson Cancer Center to research and develop cancer therapies, including KRAS inhibitors for lung and gastrointestinal cancers and an antibody agonizing TNFRSF10B. The partners established a Virtual Research and Development Center to conduct the joint research...